Tandem t:slim X2 User Manual page 302

CHAPTER 32 • Overview of Control-IQ Technology Clinical Studies
DCLP3: Percentage of CGM Use Over the 6-Month Period (N=168)
Weeks 1–4
Weeks 5–8
Weeks 9–12
Weeks 12–16
Weeks 17–20
Weeks 21–End
Overall
*The denominator is the total possible time within the 6-month study period. CGM use includes warm-up time.
DCLP5: Percentage of CGM Use Over the 4-Month Period (N=101)
Weeks 1–4
Weeks 5–8
Weeks 9–12
Weeks 13–End
Overall
*The denominator is the total possible time within the 4-month study period. CGM use includes warm-up time.
300
Control-IQ*
96%
96%
96%
96%
97%
95%
96%
Control-IQ*
98%
98%
98%
97%
97%
SAP*
94%
93%
91%
90%
91%
90%
91%
SAP*
95%
96%
96%
97%
96%